Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index.] | Recenti Prog Med | 2024 | 39550678 | PubTator, text mining | PubMed |
| Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation. | J Nucl Med | 2024 | 39542697 | PubTator, text mining | PubMed |
| Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook. | Mol Pharm | 2024 | 39537365 | PubTator, text mining | PubMed |
| Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis. | BJC Rep | 2024 | 39528547 | PubTator, text mining | PubMed |
| Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment. | Drug Des Devel Ther | 2024 | 39525044 | PubTator, text mining | PubMed |
| Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis. | BMC Nephrol | 2024 | 39522022 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. | Cancers (Basel) | 2024 | 39518062 | PubTator, text mining | PubMed |
| 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer. | J Clin Invest | 2024 | 39509246 | PubTator, text mining | PubMed |
| Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. | Breast | 2024 | 39500221 | PubTator, text mining | PubMed |
| TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. | Future Oncol | 2024 | 39469838 | PubTator, text mining | PubMed |
| Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives. | Med Oncol | 2024 | 39460856 | PubTator, text mining | PubMed |
| Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth. | Pharmaceutics | 2024 | 39458590 | PubTator, text mining | PubMed |
| [The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.] | Recenti Prog Med | 2024 | 39446008 | PubTator, text mining | PubMed |
| A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer. | Crit Rev Oncol Hematol | 2024 | 39433229 | PubTator, text mining | PubMed |
| TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis. | Exp Dermatol | 2024 | 39422290 | PubTator, text mining | PubMed |
| Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer. | Biomed Pharmacother | 2024 | 39418963 | PubTator, text mining | PubMed |
| Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery. | Sci Transl Med | 2024 | 39413161 | PubTator, text mining | PubMed |
| Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma. | J Gastric Cancer | 2024 | 39375055 | PubTator, text mining | PubMed |
| The genomic and transcriptomic landscape of metastastic urothelial cancer. | Nat Commun | 2024 | 39366934 | PubTator, text mining | PubMed |
| mTOR activity paces human blastocyst stage developmental progression. | Cell | 2024 | 39332412 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=35